

**Brandes Investment Partners**  
**Global Equity Strategy Notes**  
**Second Quarter 2024 (April 1 – June 30, 2024)**

The Brandes Global Equity Strategy declined -1.65% net of fees and 1.56% gross of fees, underperforming its benchmark, the MSCI World Index, which gained 2.63% in the quarter, and the MSCI World Value Index, which was down 1.20%.

<b>Annualized total return as of June 30, 2024</b>	<b>1-year</b>	<b>5-year</b>	<b>10-year</b>
Brandes Global Equity Composite (net)	20.65%	11.14%	6.64%
Brandes Global Equity Composite (gross)	21.17%	11.71%	7.21%
MSCI World Index	20.19%	11.76%	9.15%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

**Positive Contributors**

Bank holdings were among the strongest performers, led by Austria-domiciled Erste Group Bank, U.K.-based NatWest, and Singapore’s DBS Group.

Select technology-related holdings also helped returns, notably U.S.-based Micron Technology and Alphabet, as well as Taiwan Semiconductor Manufacturing Company (TSMC). TSMC received Taiwanese government approval to finance the construction of manufacturing facilities in Japan and the U.S., positioning it to support the growing demand for artificial intelligence and high-performance computing technologies.

Other contributors included several holdings in the United Kingdom. In addition to NatWest, tobacco company Imperial Brands and energy firm Shell lifted returns, as did aerospace and defense holding Rolls-Royce. Rolls-Royce continued to benefit from the ongoing recovery in its end-markets, and the market reacted favorably to the firm’s announcement it would leave its 2024 guidance unchanged.

**Performance Detractors**

Holdings in health care detracted from performance, most notably U.S.-based Fortrea, CVS, and Cardinal Health.

Shares of CVS declined after the company cut its earnings outlook on rising Medicare Advantage costs. Despite the headwinds, CVS continues to enjoy a favorable competitive position as a vertically integrated company in the health care sector. Trading at a high single-digit multiple of earnings following the share-price decline, CVS remains a compelling investment opportunity, in our opinion.

Several of our technology holdings also dampened returns, led by U.S.-based IT services firm Amdocs. Moreover, our significant underweight to the sector hurt relative returns as it was the strongest performing part of the benchmark.

Other detractors included U.S. media firm Comcast and Ireland-domiciled construction materials company CRH. Furthermore, several of our emerging markets holdings weighed on performance, led by Brazilian beverage firm Ambev, Chinese specialty retailer Topsports International, and Mexican real estate investment trust Fibra Uno.

**Select Activity in the Quarter**

The investment committee initiated new positions in U.K consumer healthcare company Reckitt Benckiser and Hong Kong-based insurance company AIA Group.

Reckitt Benckiser is a multinational consumer goods company, with operations in over 60 countries across three business units: consumer health, hygiene, and nutrition. The company’s brands are strong, particularly on a country-specific basis, such as Lysol in the U.S. and Dettol in India. Over the past several years, the management team has been focusing on

achieving higher-than-category average growth for the company's brands and on increasing margins through positive operating leverage and productivity-related efficiency improvements.

During the pandemic, Reckitt experienced a short-term surge in demand for its hygiene products. However, the associated stock-price increase was not sustained, and Reckitt's shares remained largely range-bound for five years prior to their recent decline. The company's shares have come under pressure after it reported weaker-than-expected growth and profitability for fiscal year 2023. While it has improved its margins over the past few years, Reckitt will likely face slower growth in the near term as it cycles through last year's elevated base, driven by infant formula recall by Abbott Laboratories (Reckitt's main competitor) and a robust cold and flu season. Additionally, concerns about potential liability related to its pre-term infant formula business in the U.S. further weighed on investor sentiment after the company lost a legal case earlier this year. Reckitt faces additional related legal cases, as does Abbott Laboratories.

Despite the headwinds, Reckitt's longer-term growth profile appears compelling to us. We appreciate its competitive position, which should allow it to grow at an above-average rate in each business category. We also believe the company has the potential for margin expansion through a combination of productivity-related cost savings and positive operating leverage. In our opinion, investor concerns about Reckitt's growth prospects and potential legal liabilities have been more than accounted for in its share price. At its current valuation, which reflects a discount to the company's historical multiples, we see Reckitt as an appealing investment opportunity.

#### ***Year-to-Date Briefing***

The Brandes Global Equity Strategy rose 8.01% net of fees and 8.23% gross of fees, underperforming its benchmark, the MSCI World Index, which increased 11.75% in the six months ended June 30, 2024, and outperforming the MSCI World Value Index, which appreciated 6.20%.

The strongest contributors included holdings in industrials, particularly Rolls-Royce and Brazilian regional jet manufacturer Embraer. Select holdings in financials also helped performance, led by U.S.-based Wells Fargo and Citigroup, U.K.-based NatWest, and Austria's Erste Group Bank.

Select holdings in technology, such as TSMC, Micron Technology, and Germany-based SAP, showed robust results, but our significant underweight to technology-related companies, both in the technology and communication services sectors, hurt relative returns. These two sectors were by far the best-performing components of the benchmark this year, up over 20% while most other sectors rose by single digits or declined.

Other detractors included holdings in health care (e.g., Spanish biotech firm Grifols, CVS, Fortrea) and consumer staples (e.g., Ambev, French retailer Carrefour). Grifols' shares declined mainly in the first quarter following a short seller's report that questioned the company's accounting and corporate governance practices. We continue to believe there is a meaningful upside potential in the company. Grifols recently completed the sale of an equity stake in Shanghai RAAS, which should help it improve its financial leverage in the near term.

#### ***Current Positioning***

The Brandes Global Equity Strategy continues to hold its key positions in the economically sensitive financials sector and the more defensive health care sector, while maintaining its largest sector underweight to technology. Geographically, we continue to hold overweight positions in the United Kingdom, France, and emerging markets, while remaining underweight in the United States and Japan. We believe the differences between the strategy and the MSCI World Index make it an excellent complement and diversifier to passive and growth-oriented strategies.

We've continued to observe a wide dispersion of sector performance in the benchmark, with companies in the technology and communication services sectors materially outperforming the MSCI World Index. Following the sector's appreciation this past year, technology has become a larger component of the MSCI World Index, and our allocation is less than half the benchmark's 26% weighting. Meanwhile, more defensive areas, such as consumer staples and health care, have underperformed the benchmark. Unsurprisingly, we have noticed more attractively valued companies in these sectors and have modestly increased our allocation over the past year.

With the valuation gap between value and growth stocks widening in the past year, we are increasingly optimistic about the return potential for value stocks. Following the outperformance of the growth index (MSCI World Growth vs. MSCI World Value), fueled largely by a few U.S. tech-related companies, value stocks are trading at the largest discount relative to growth stocks since the inception of the style indices. This valuation disparity is evident across various metrics, such as price/earnings, price/cash flow and enterprise value/sales. Historically, such valuation differentials have often signaled attractive future returns for value stocks over longer-term horizons. Notably, our portfolio, guided by our value philosophy and process, has tended to outperform the benchmark when value stocks outperformed the MSCI World Index.

Going forward, we are excited about the long-term prospects of our holdings, which in aggregate trade at more compelling valuation levels than the benchmark, in our opinion.

Term definitions: <https://www.brandes.com/termdefinitions>

The MSCI World Growth Index with gross dividends captures large and mid cap securities across developed market countries exhibiting growth style characteristics, defined using long-term forward earnings per share (EPS) growth rate, short-term forward EPS growth rate, current internal growth rate, long-term historical EPS growth trend, and long-term historical sales per share growth trend.

The MSCI World Index with net dividends captures large and mid cap representation of developed markets.

The MSCI World Value Index with gross dividends captures large and mid cap securities across developed market countries exhibiting value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

**United States:** Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

**Singapore/Asia:** FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

**Canada:** FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.